Terlipressin

Basic Information


CAS ID: 14636-12-5
Molecular Formula: C52H74N16O15S2
Molecular Weight: 1227.4 g/mol
Monoisotopic Mass: 1226.496 g/mol
Class: Peptide
Natural Product: No
Other Names: TERLIPRESSIN | VARIQUEL
Analysis: Drug repositioning mechanism analysis

N O S S O NH O NH O NH O NH O NH O NH2 O NH2 OH NH O NH O NH O H2N O NH H2N O NH O NH2


Compound Structure and Identifier


InChI: InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1 See All
InChI Key: BENFXAYNYRLAIU-QSVFAHTRSA-N
Smiles: C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N See All
Molfile: Download


Related Target



Related Fibrosis Property


Trial Record 1

ClinicalTrial ID NCT03144713 Disease Liver fibrosis
Phase Not Applicable Status Completed
First Received May 9, 2017 Last Verified September 5, 2018
Sponsor Institute of Liver and Biliary Sciences, India

Trial Record 2

ClinicalTrial ID NCT00986817 Disease Liver fibrosis
Phase Phase 3 Status Completed
First Received September 30, 2009 Last Verified June 15, 2015
Sponsor Assistance Publique - Hôpitaux de Paris

Trial Record 3

ClinicalTrial ID NCT00966355 Disease Fibrosis
Phase Phase 4 Status Completed
First Received August 26, 2009 Last Verified March 19, 2018
Sponsor Korea University

Trial Record 4

ClinicalTrial ID NCT03107091 Disease Liver fibrosis
Phase Phase 2 Status Recruiting
First Received April 11, 2017 Last Verified January 18, 2018
Sponsor BioVie Inc.

Trial Record 5

ClinicalTrial ID NCT00534677 Disease Liver fibrosis
Phase Phase 4 Status Completed
First Received September 26, 2007 Last Verified December 5, 2007
Sponsor Aga Khan University

Trial Record 6

ClinicalTrial ID NCT00115947 Disease Liver fibrosis
Phase Phase 2,Phase 3 Status Completed
First Received June 27, 2005 Last Verified March 9, 2006
Sponsor Hvidovre University Hospital

Trial Record 7

ClinicalTrial ID NCT02468063 Disease Liver fibrosis
Phase Not Applicable Status Completed
First Received June 10, 2015 Last Verified November 6, 2017
Sponsor Institute of Liver and Biliary Sciences, India

Trial Record 8

ClinicalTrial ID NCT01836224 Disease Liver fibrosis
Phase Not Applicable Status Completed
First Received April 19, 2013 Last Verified November 22, 2016
Sponsor Institute of Liver and Biliary Sciences, India

Trial Record 9

ClinicalTrial ID NCT00628160 Disease Liver fibrosis
Phase Phase 2,Phase 3 Status Completed
First Received March 4, 2008 Last Verified February 24, 2016
Sponsor Hospital Clinic of Barcelona

Trial Record 10

ClinicalTrial ID NCT01640964 Disease Liver fibrosis
Phase Phase 2 Status Completed
First Received July 16, 2012 Last Verified March 15, 2016
Sponsor Novartis Pharmaceuticals

Trial Record 11

ClinicalTrial ID NCT00742690 Disease Liver fibrosis
Phase Phase 2,Phase 3 Status Unknown
First Received August 28, 2008 Last Verified October 15, 2014
Sponsor University of Padova

Trial Record 12

ClinicalTrial ID NCT00742339 Disease Liver fibrosis
Phase Phase 2,Phase 3 Status Terminated
First Received August 27, 2008 Last Verified October 15, 2014
Sponsor University of Padova

Trial Record 13

ClinicalTrial ID NCT00287664 Disease Liver fibrosis
Phase Phase 4 Status Suspended
First Received February 7, 2006 Last Verified April 11, 2007
Sponsor Hospital Clinic of Barcelona

Related Link


PubChem: 72081
ChEMBL: CHEMBL2135460